IBCSG 20-98 / BIG 2-98 / Taxotere

  • A phase III trial to evaluate the activity of docetaxtel given either sequentially or in combination with doxorubicin, followed by CMF, in comparison to doxorubicin alone or in combination with cyclophosphamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients

  • Study Chairs
    BIG: Dr. Martine Piccart - Brussels, Belgium
    IBCSG: Dr. Prue Francis - Melbourne, Australia
    SAKK: Dr. Lucien Perey - Lausanne, Switzerland
    SAKK: Dr. Dagmar Hess - St. Gallen, Switzerland

    Monitoring
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    June 1998

    Date of Closure
    June 26, 2001

    Targeted Accrual
    2730 patients

    Final Accrual
    2890 patients

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login